LIXTE Biotechnology Reports Preclinical Results of Striking Anti-Cancer Activity of LB-100
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) reports that Professor René Bernards, Netherlands Cancer Institute, Amsterdam has presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100 at the Annual Meeting of America Association for Cancer Research in New Orleans, LA. [stock_market_widget type=”inline-label” template=”basic9″ color=”orange” assets=”LIXT” api=”yf”] [stock_market_widget type=”chart” template=”basic” color=”orange” assets=”LIXT” …